Expression of immunoglobulin-like transcript 4 as an inhibitory receptor in patients with psoriatic arthritis
Autor: | Alberto Bergamini, Paola Conigliaro, Roberto Perricone, Maria Sole Chimenti, G. Gigliucci, Paola Triggianese, Carlo Perricone, Maria Domenica Guarino |
---|---|
Rok vydání: | 2016 |
Předmět: |
0301 basic medicine
Biochemistry 03 medical and health sciences Psoriatic arthritis 0302 clinical medicine Adalimumab medicine innate immunity psoriatic arthritis 030203 arthritis & rheumatology CD86 CD40 biology Antitumour necrosis factor-α business.industry Medicine (all) Monocyte Gene/Molecular Research on Immune-Mediated Diseases Biochemistry (medical) hemic and immune systems immunoglobulin-like transcript 4 Cell Biology General Medicine medicine.disease Settore MED/16 - Reumatologia 030104 developmental biology medicine.anatomical_structure TNF-α Immunology biology.protein ILT4 Tumor necrosis factor alpha Antibody business CD80 medicine.drug |
Zdroj: | The Journal of International Medical Research |
ISSN: | 1473-2300 0300-0605 |
Popis: | Objectives To investigate the presence of immunoglobulin-like transcript (ILT)4 and costimulatory proteins (CD40, CD80 and CD86), as well as tumour necrosis factor (TNF)-α production in antigen-presenting cells (APCs) from patients with psoriatic arthritis, before and after treatment with the antitumour necrosis factor-α therapy, adalimumab. Methods Peripheral blood monocytes from patients with psoriatic arthritis and healthy controls were cultured with CD40 ligand (CD40L) to stimulate differentiation to APCs. Cell-surface phenotype was analysed via fluorescence-activated cell sorting. Results CD40L-stimulation resulted in significantly more ILT4+ monocytes in cultures from control subjects ( n = 21) than those from patients ( n = 20). ILT4-positivity on CD40L-stimulated monocytes was negatively correlated with disease activity in patients. Adalimumab treatment resulted in significant increases from baseline in ILT4-positivity, and in decreases in CD40, CD80 and CD86-positivity in monocytes from patients. Conclusion The effect of adalimumab on monocyte surface phenotype may be due to modification of the inflammatory milieu associated with therapy-induced reduction of disease activity in psoriatic arthritis. |
Databáze: | OpenAIRE |
Externí odkaz: |